Personalize therapy of lung cancer patients with acquired TKI-resistance mutation T790M in the
Mutations in the epidermal growth factor receptor (EGFR) gene are predictive of the response to EGFR tyrosine kinase inhibitors (TKIs). The ViennaLab assays identify thirty EGFR mutations relevant for non-small cell lung cancer (NSCLC) TKI therapy.
EGFR & EGFR T790M
- NSCLC comprises approximately 85% of all lung cancers. Tumor specimens from patients should be tested for the presence of EGFR mutations prior to TKI treatment.
- Patients carrying EGFR mutations known as `activating mutations´ may benefit from first- or second- or third-generation TKIs. Patients carrying the `resistance mutation´ EGFR T790M may benefit from the third-generation TKI osimertinib.
- The EGFR XL StripAssay® and EGFR T790M RealFast™ Assay are designed to assist clinicians in the stratification of patients considered for TKI therapy.
|EGFR XL StripAssay®||5-630||20 tests||
|EGFR T790M RealFast™ Assay||8-110 8-113||100 rxn 32 rxn||